JP7709379B2 - イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用 - Google Patents

イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用

Info

Publication number
JP7709379B2
JP7709379B2 JP2021550133A JP2021550133A JP7709379B2 JP 7709379 B2 JP7709379 B2 JP 7709379B2 JP 2021550133 A JP2021550133 A JP 2021550133A JP 2021550133 A JP2021550133 A JP 2021550133A JP 7709379 B2 JP7709379 B2 JP 7709379B2
Authority
JP
Japan
Prior art keywords
optionally substituted
independently selected
compound
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021550133A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020176654A5 (https=
JP2022521797A (ja
JP2022521797A5 (https=
Inventor
イワノヴィッチ，エドウィン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madera Therapeutics LLC
Original Assignee
Madera Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madera Therapeutics LLC filed Critical Madera Therapeutics LLC
Publication of JP2022521797A publication Critical patent/JP2022521797A/ja
Publication of JPWO2020176654A5 publication Critical patent/JPWO2020176654A5/ja
Publication of JP2022521797A5 publication Critical patent/JP2022521797A5/ja
Application granted granted Critical
Publication of JP7709379B2 publication Critical patent/JP7709379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021550133A 2019-02-27 2020-02-26 イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用 Active JP7709379B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962811432P 2019-02-27 2019-02-27
US62/811,432 2019-02-27
US201962819204P 2019-03-15 2019-03-15
US62/819,204 2019-03-15
US201962825667P 2019-03-28 2019-03-28
US62/825,667 2019-03-28
US201962840254P 2019-04-29 2019-04-29
US62/840,254 2019-04-29
US201962871694P 2019-07-08 2019-07-08
US62/871,694 2019-07-08
US201962885055P 2019-08-09 2019-08-09
US62/885,055 2019-08-09
US201962901142P 2019-09-16 2019-09-16
US62/901,142 2019-09-16
US201962931043P 2019-11-05 2019-11-05
US62/931,043 2019-11-05
US202062975088P 2020-02-11 2020-02-11
US62/975,088 2020-02-11
PCT/US2020/019944 WO2020176654A1 (en) 2019-02-27 2020-02-26 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Publications (4)

Publication Number Publication Date
JP2022521797A JP2022521797A (ja) 2022-04-12
JPWO2020176654A5 JPWO2020176654A5 (https=) 2023-02-17
JP2022521797A5 JP2022521797A5 (https=) 2023-02-17
JP7709379B2 true JP7709379B2 (ja) 2025-07-16

Family

ID=72238693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550133A Active JP7709379B2 (ja) 2019-02-27 2020-02-26 イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用

Country Status (7)

Country Link
US (1) US12459945B2 (https=)
EP (1) EP3930714A4 (https=)
JP (1) JP7709379B2 (https=)
CN (2) CN113795251B (https=)
AU (2) AU2020228047B2 (https=)
CA (1) CA3131740A1 (https=)
WO (1) WO2020176654A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
EP4337214A4 (en) * 2021-05-13 2025-01-29 Chimerix, Inc. USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMAS
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
WO2024030645A1 (en) * 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
WO2024199457A1 (zh) * 2023-03-31 2024-10-03 苏州安赛隆医药科技有限公司 并环结构化合物、其制备方法及其用途以及药物组合物及其用途
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
EP4488279A1 (en) * 2023-07-03 2025-01-08 Centro Atlantico del Medicamento S.A (Ceamed, S.A) Substituted hexahydro-2h-pyrazino[1,2-a]pyrazin-1(6h)-one derivatives as activators of human caseinolytic protease p (hsclpp)
WO2025011546A1 (en) * 2023-07-10 2025-01-16 Acelon Therapeutics Human caseinolytic protease p agonists and uses thereof
CN119306718A (zh) * 2023-07-11 2025-01-14 中科中山药物创新研究院 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524941A (ja) 2007-04-20 2010-07-22 シェーリング コーポレイション ピリミジノン誘導体およびそれらの使用方法
JP2022520997A (ja) 2019-02-22 2022-04-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム イミプリドンを使用する方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
DE59408453D1 (de) 1993-04-23 1999-08-12 Hoechst Ag Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
US20110275647A1 (en) * 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
WO2012079164A1 (en) 2010-12-16 2012-06-21 The Governing Council Of The University Of Toronto Activators of cylindrical proteases
LT3662910T (lt) 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
AU2017310529B2 (en) 2016-08-12 2021-08-19 Edwin J. Iwanowicz Protein kinase regulators
WO2018031987A1 (en) 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524941A (ja) 2007-04-20 2010-07-22 シェーリング コーポレイション ピリミジノン誘導体およびそれらの使用方法
JP2022520997A (ja) 2019-02-22 2022-04-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム イミプリドンを使用する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REGISTRY (STN) [online]，2010.12.02[検索日 2023.11.08] CAS登録番号 1347347-38-9
REGISTRY (STN) [online]，2017.08.28[検索日 2023.11.08] CAS登録番号 2121092-64-4

Also Published As

Publication number Publication date
CN121758447A (zh) 2026-03-31
EP3930714A4 (en) 2022-10-26
WO2020176654A1 (en) 2020-09-03
AU2026201069A1 (en) 2026-03-12
US12459945B2 (en) 2025-11-04
AU2020228047B2 (en) 2025-11-20
US20220089596A1 (en) 2022-03-24
JP2022521797A (ja) 2022-04-12
WO2020176654A8 (en) 2020-10-08
EP3930714A1 (en) 2022-01-05
CN113795251B (zh) 2026-01-13
AU2020228047A1 (en) 2021-09-30
CA3131740A1 (en) 2020-09-03
CN113795251A (zh) 2021-12-14

Similar Documents

Publication Publication Date Title
JP7709379B2 (ja) イミプリドン様薬剤に対する薬物反応のバイオマーカとしてのカゼイン分解プロテアーゼｐの機能の使用
CN108883112B (zh) 用于癌症患者分级和癌症治疗的化合物、组合物和方法
CN110392678B (zh) 用于ido和tdo调节的化合物和方法，以及其适应症
JP5956653B2 (ja) １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JP7850460B2 (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
AU2020366135B2 (en) Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
KR20180134860A (ko) 암의 치료를 위한 taf1 억제제
EP3496724B1 (en) Protein kinase regulators
US20230339947A1 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
WO2021202900A1 (en) 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
TW201002716A (en) Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
EP4612154A1 (en) Regulators of porphyrin and intermediates
JP2020526495A (ja) ヘテロクロマチン遺伝子抑制阻害薬
WO2025151850A1 (en) Spirocycle acrylamides that stereo- and site-selectively degrade the transcriptional and dna-damage response protein ercc3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250704

R150 Certificate of patent or registration of utility model

Ref document number: 7709379

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150